J Korean Ophthalmol Soc > Volume 61(1); 2020 > Article
Journal of the Korean Ophthalmological Society 2020;61(1):41-50.
DOI: https://doi.org/10.3341/jkos.2020.61.1.41    Published online January 15, 2020.
Comparision of Hyperreflective Foci after Treatment of Diabetic Macular Edema Patients between Intravitreal Injections.
Minjin Kim, Kibum Park, Myeong Yeon Yi, Sung Jin Lee
1Department of Ophthalmology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. wismile@schmc.ac.kr
2Soo Eye Clinic, Seoul, Korea.
당뇨황반부종에서 유리체 내 주사제에 따른 치료 전후 고반사점 변화 비교
김민진1 · 박기범1 · 이명연2 · 이성진1
순천향대학교 의과대학 서울병원 안과학교실1, 수안과의원2
Correspondence:  Sung Jin Lee,
Email: wismile@schmc.ac.kr
Received: 4 July 2019   • Revised: 16 August 2019   • Accepted: 30 December 2019
Abstract
PURPOSE
To compare the outcomes in patients with diabetic macular edema (DME) treated with intravitreal dexamethasone implants and intravitreal bevacizumab injections. METHODS: A retrospective cohort study was designed using 66 patients with DME treated with intravitreal dexamethasone (n = 35; 35 eyes) and intravitreal bevacizumab (n = 31; 31 eyes). Post-treatment changes in hyperreflective foci in the inner and outer retina were characterized using optical coherence tomography, central macular thickness, outer limiting membrane, and photoreceptor inner segment-outer segment junctions. Visual acuities were analyzed 4 weeks after bevacizumab injections and 8 weeks after dexamethasone injections. RESULTS: Both groups showed a decrease in the number of hyperreflective foci after treatment: from 10.6 ± 11.8 to 6.3 ± 5.9 (p = 0.005) in the intravitreal dexamethasone implant group and from 11.6 ± 8.5 to 7.7 ± 6.7 (p < 0.001) in the intravitreal bevacizumab injection group. The mean central macular thickness in the dexamethasone group changed significantly from 586.8 µm to 297.7 µm after treatment and the visual acuity improved significantly from 0.33 logMAR to 0.38 logMAR after treatment (p < 0.001 and p = 0.018, respectively). The mean central macular thickness in the bevacizumab group showed a significant decrease from 467.1 µm to 353.2 µm after treatment (p < 0.001), but there was no significant change in the visual acuities: 0.34 logMAR to 0.32 logMAR after treatment (p = 0.464). CONCLUSIONS: Both intravitreal dexamethasone implants and bevacizumab treatments in patients with DME showed improved outcomes including a decrease in hyperreflective foci shown by optical coherence tomography.
Key Words: Bevacizumab;Dexamethasone;Diabetic macular edema;Hyperreflective foci


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next